tetano
Editor, Senior Moderator
Rheumatol Ther
. 2024 Jan 6.
doi: 10.1007/s40744-023-00632-3. Online ahead of print. Characteristics of COVID-19 and Impact of Disease Activity in Patients with Adult-Onset Still's Disease
Xinyue Hong[SUP] #[/SUP][SUP] 1 [/SUP], Xiaoming Wang[SUP] #[/SUP][SUP] 2 [/SUP], Ningqi Dai[SUP] #[/SUP][SUP] 1 [/SUP], Yue Sun[SUP] 1 [/SUP], Honglei Liu[SUP] 1 [/SUP], Xiaobing Cheng[SUP] 1 [/SUP], Junna Ye[SUP] 1 [/SUP], Hui Shi[SUP] 1 [/SUP], Qiongyi Hu[SUP] 1 [/SUP], Jianfen Meng[SUP] 1 [/SUP], Zhuochao Zhou[SUP] 1 [/SUP], Chengde Yang[SUP] 1 [/SUP], Jialin Teng[SUP] 1 [/SUP], Yutong Su[SUP] 1 [/SUP], Huihui Chi[SUP] 3 [/SUP]
Affiliations
Introduction: This study aimed to characterize the morbidity, hospitalization, and mortality rates among patients with adult-onset Still's disease (AOSD) affected by coronavirus disease 2019 (COVID-19) and explore the impact of COVID-19 on the disease activity of AOSD.
Methods: Data on the clinical and demographic characteristics, COVID-19-related symptoms, and outcomes were retrospectively collected. Patients were stratified according to COVID-19 severity and associations between risk factors and outcomes were analyzed using multivariate logistic regression. The disease activity of patients with AOSD flares after COVID-19 was described.
Results: A total of 188 patients with AOSD were followed up, of whom 75.5% (n = 142) had a confirmed or highly suspected COVID-19. Patients on medium or high-dose oral glucocorticoids or Janus kinase (JAK) inhibitors were at increased risk of developing moderate to severe COVID-19. Six patients suffered flares of AOSD following COVID-19 in a short period; however, the relapse rate was not statistically increased compared with patients without COVID-19.
Conclusion: Patients with AOSD receiving medium or high-dose glucocorticoid therapy or JAK inhibitors had worse COVID-19 outcomes. Further work is needed to explore risk factors affecting COVID-19 outcomes and the impact of COVID-19 on disease activity in AOSD.
Keywords: Adult-onset Still’s disease; COVID-19; Glucocorticoids; JAK inhibitors.
. 2024 Jan 6.
doi: 10.1007/s40744-023-00632-3. Online ahead of print. Characteristics of COVID-19 and Impact of Disease Activity in Patients with Adult-Onset Still's Disease
Xinyue Hong[SUP] #[/SUP][SUP] 1 [/SUP], Xiaoming Wang[SUP] #[/SUP][SUP] 2 [/SUP], Ningqi Dai[SUP] #[/SUP][SUP] 1 [/SUP], Yue Sun[SUP] 1 [/SUP], Honglei Liu[SUP] 1 [/SUP], Xiaobing Cheng[SUP] 1 [/SUP], Junna Ye[SUP] 1 [/SUP], Hui Shi[SUP] 1 [/SUP], Qiongyi Hu[SUP] 1 [/SUP], Jianfen Meng[SUP] 1 [/SUP], Zhuochao Zhou[SUP] 1 [/SUP], Chengde Yang[SUP] 1 [/SUP], Jialin Teng[SUP] 1 [/SUP], Yutong Su[SUP] 1 [/SUP], Huihui Chi[SUP] 3 [/SUP]
Affiliations
- PMID: 38183598
- DOI: 10.1007/s40744-023-00632-3
Introduction: This study aimed to characterize the morbidity, hospitalization, and mortality rates among patients with adult-onset Still's disease (AOSD) affected by coronavirus disease 2019 (COVID-19) and explore the impact of COVID-19 on the disease activity of AOSD.
Methods: Data on the clinical and demographic characteristics, COVID-19-related symptoms, and outcomes were retrospectively collected. Patients were stratified according to COVID-19 severity and associations between risk factors and outcomes were analyzed using multivariate logistic regression. The disease activity of patients with AOSD flares after COVID-19 was described.
Results: A total of 188 patients with AOSD were followed up, of whom 75.5% (n = 142) had a confirmed or highly suspected COVID-19. Patients on medium or high-dose oral glucocorticoids or Janus kinase (JAK) inhibitors were at increased risk of developing moderate to severe COVID-19. Six patients suffered flares of AOSD following COVID-19 in a short period; however, the relapse rate was not statistically increased compared with patients without COVID-19.
Conclusion: Patients with AOSD receiving medium or high-dose glucocorticoid therapy or JAK inhibitors had worse COVID-19 outcomes. Further work is needed to explore risk factors affecting COVID-19 outcomes and the impact of COVID-19 on disease activity in AOSD.
Keywords: Adult-onset Still’s disease; COVID-19; Glucocorticoids; JAK inhibitors.